← Back to Home

Novartis partners with Abogen to develop mRNA immunotherapies in deal potentially worth nearly $7.8 billion

Getting human cells to produce therapeutic molecules that direct T cells is the scientific core of this collaboration. Novartis will pay $575 million upfront, but the substantial additional payments are conditional, and whether the therapies can safely improve autoimmune diseases still awaits clinical evidence.

By SURL BioNews

Delivering instructions for making therapeutic molecules into the human body, allowing cells to take over production, is one avenue being explored for mRNA beyond vaccines. On October 2, Novartis announced a collaboration with China’s Abogen Biosciences to bring this concept to autoimmune diseases, aiming to use molecules produced inside the body to direct T cells to eliminate disease-related B cells.

The licensing and option agreement has a potential total value of nearly $7.8 billion. Under terms disclosed in Abogen’s announcement and by its legal adviser Jones Day, Novartis will obtain an exclusive worldwide license to the lead drug candidate ABO2203, along with exclusive licensing options for other RNA platform programs. Reuters also confirmed that the collaboration covers rights to ABO2203 and options for other therapies.

The committed upfront payment is $575 million. Approximately $7.2 billion in additional payments is contingent on Novartis exercising options for all relevant programs and achieving agreed development, regulatory and commercial milestones. Abogen may also receive royalties on future sales. The nearly $7.8 billion therefore represents potential payments if multiple programs advance successfully; it cannot be treated as funding already secured.

ABO2203 is an mRNA-encoded CD19×CD3 T-cell engager. It provides human cells with instructions for making therapeutic molecules. The resulting molecules then link CD3 on T cells with CD19 on B cells, directing an immune attack. This design changes how the therapeutic molecules are produced and delivered; whether B-cell depletion can translate into lasting disease control still needs to be answered in human trials.

The clinical information currently available remains preliminary. BioPharma Dive reported that Abogen released initial data in April on ABO2203 in relapsed or refractory B-cell non-Hodgkin lymphoma. The report also noted that three participants experienced significant adverse events, including decreases in white blood cells and clotting-related proteins, which subsequently subsided during the trial. These experiences in cancer patients cannot directly establish the therapy’s safety and benefit in autoimmune diseases.

For Novartis, the collaboration also comes as investors reassess its dealmaking strategy. Reuters reported that drugs the company previously acquired had encountered a series of trial setbacks. Novartis said Abogen’s RNA technology could complement its existing autoimmune disease treatment portfolio. Gillian Hollenstein, a fund manager who holds Novartis shares, believes that a smaller upfront commitment helps improve the deal’s risk profile, but that the company still needs later-stage assets with greater predictability.

The agreement gives Abogen resources to advance its platform while leaving Novartis room to expand the collaboration. What ultimately determines its value will be whether ABO2203 can demonstrate acceptable safety and sustained efficacy in patients with autoimmune diseases. The size of the deal alone cannot yet answer these clinical questions.

References

  1. biopharmadive.com
  2. Reuters via MarketScreener
  3. Jones Day